Block TIGIT/PD-L1 at the same time! Roche tiragolumab and Tecentriq combination first-line treatment of PD-L1-positive lung cancer shows strong efficacy!
-
Last Update: 2020-05-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
2020 May 14 News /BioValleyBIOON / - Roche (Roche) subsidiary Genentech recently announced positive results from a phase II trial CITYSCAPE the test (NSCLC) patients conducted in PD-L1-positive metastatic non-small cell lung cancer, evaluation of anti-PD-L1 therapy Tecentriq (especially good odd, common name: atezolizumab, Art natalizumab) and tiragolumab combination therapy, Tecentriq monotherapy therapy for efficacy and safety of initial (first-line) treatmenttiragolumab is a novel cancer immunotherapy targeting immune checkpoint protein binding of TIGIT expression on immune cellsTIGIT and PD-L1 plays an important role both in immunosuppressionThis block may be two waysenhance the anti-tumor activityThe primary endpoint of the trialCITYSCAPE analysis: the intention-to-treat patient population (ITT), compared to the monotherapy Tecentriq, Tecentriq + tiragolumab combination therapy while achieving the two primary endpoints: objective response rate (ORR) a significant increase (31.3% vs16.2%), the risk of disease progression or death was significantly reduced by 34% (progression-free survival [PFS]; median PFS: 5.4 months vs3.6 months; HR = 0.47,95% CI: 0.37-0.90)expression of PD-L1 (TPS≥50%) patients conducted an exploratory analysis show: Tecentriq compared with monotherapy, Tecentriq + tiragolumab combination treatment significantly improved ORR (55.2% vs17.2%) the risk of disease progression or death was significantly reduced 67% (median PFS: not reached vs3.9 months; HR = 0.33,95% CI: 0.15-0.72)at 6 months follow-up, and high expression of PD-L1 ITT population, Tecentriq + ORR and PFS tiragolumab combined treatment group were continued to improve, no new safety signals were observedIn this test, Tecentriq well tolerated and has tiragolumab combination therapy, all due to adverse events (AE) in the incidence of grade 3 or above all, Tecentriq monotherapy and combination therapy treatment similar (41.8% vs44.1%)CITYSCAPE complete test results will be published in 2020 virtual scientific meeting of the American Society of Clinical Oncology (ASCO), held on May 29-31Chief Medical Officer and LeviGarraway MD, head of Roche's global product development, said: "We are delighted to share the results of the first randomized trials of anti-TIGIT therapy, shows that our novel cancer immunotherapy tiragolumab used in combination with Tecentriq have been encouraging the efficacy and safety of .TIGIT is an expression in the immune cells of the immune checkpoint proteins identified by our own scientistsby blocking PD-L1 pathway TIGIT and at the same time, we hope to deepen the patient's response to immunotherapy, expand range may benefit people"
tiragolumab is a monoclonal antibody, capable of targeting binding of a protein receptor on immune cells TIGIT expressionBy combining TIGIT, tiragolumab can block the interaction of the protein with one TIGIT poliovirus receptor (PVR, or CD155) namedTIGIT binding to PVR may inhibit the immune responseTecentriq belonging to the anti-PD- (L) 1 therapy, the drug is a monoclonal antibody, and a tumor cell binding to target a tumor infiltrating called PD expressed on immune cells -L1 protein, blocking its interaction with B7.1 and PD-1 receptorBy inhibiting PD-L1, Tecentriq can activate T cells, the drug has potential as a cancer immunotherapy, targeted therapy drugs and basic compatibility of various forms of cancer chemotherapyTIGIT and PD-L1 blockade may be synergistic activation of T cells, enhance the anti-tumoractivity of NK cellsThis is tiragolumab scientific basis for combination therapy studies with TecentriqAs part of a new dedicated to exploring Genentech immunization regimens and combinations, which recently initiated a phase III clinical trial of a 2, tiragolumab + Tecentriq assess combination therapy for a specific type of lung cancer efficacy in patients (SKYSCRAPER-01, SKYSCRAPER-02)tiragolumab also assessed other solid tumors and blood tumors, the additional drug treatment of solid tumors Ia / b of the results will also be ASCO2020Up to now, Tecentriq in the United States, the European Union and other countries in the world approved as a monotherapy, as well as joint targeted therapy and / or chemotherapy, the treatment of various types of non-small cell lung cancer (NSCLC) and small cell lung cancer ( SCLC), certain types of metastatic urothelial carcinoma (mUC), PD-L1 positive a triple negative breast cancer(TNBC)in China, Tecentriq (especially good odd) was approved in February 2020, in combination with chemotherapy (carboplatin + etoposide), first-line therapy in patients with extensive stage small cell lung cancer (ES-SCLC)It is worth mentioning that, Tecentriq following the December 10, 2019 the State Food and Drug Administration approvedEsilikang anti-PD-L1 therapy Imfinzi (England fly where generic name: durvalumab after cutting of Li You monoclonal), China approved drugs second PD-L1 Plus 6 PD-1 drugs, currently listed on the PD-1 / L1 drugs reached eight a (Biovalley Bioon.com) ORIGINAL: GenentechtoPresentFirstClinicalDataonNovelAnti-TIGITCancerImmunotherapyTiragolumabatASCO
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.